国产精品又长又粗又爽又黄的毛片, 国产AV无码专区亚洲AV毛片搜, 丰满人妻被猛烈进入中文字幕四川, 国产精品一区二区三区国产女人喷,亚洲国产欧美日韩图片在线人,潘娇娇337p人艺体艺术,成人免费无码大片a毛片古装,一本到高清视频免费,人妻在线视频免费看

更新于 今天

RPM(魯皖晉蒙)(J10109)

1.3-2.5萬(wàn)

職位描述

醫(yī)院呼吸風(fēng)濕免疫腫瘤放療
崗位職責(zé):
1、根據(jù)中央市場(chǎng)策略和推廣項(xiàng)目,在負(fù)責(zé)區(qū)域執(zhí)行落地;
2、建立維護(hù)專家網(wǎng)絡(luò),并與當(dāng)?shù)豄OL專家建立有效和專業(yè)的合作關(guān)系,以支持品牌的醫(yī)學(xué)、市場(chǎng)市場(chǎng)推廣;
3、參加區(qū)域銷售會(huì)議,分享市場(chǎng)趨勢(shì)、競(jìng)爭(zhēng)對(duì)手動(dòng)態(tài)和產(chǎn)品信息,幫助銷售發(fā)現(xiàn)市場(chǎng)問(wèn)題和機(jī)會(huì)點(diǎn);
4、結(jié)合區(qū)域?qū)嶋H情況制定區(qū)域業(yè)務(wù)發(fā)展目標(biāo)及落地執(zhí)行市場(chǎng)推廣策略,做好區(qū)域數(shù)據(jù)及微觀市場(chǎng)分析,組織參與有效的學(xué)術(shù)推廣活動(dòng),把控區(qū)域?qū)W術(shù)活動(dòng)質(zhì)量;
5、參與銷售團(tuán)隊(duì)的協(xié)訪,挖掘客戶信息,幫助銷售維護(hù)重要客戶,并解決產(chǎn)品相關(guān)問(wèn)題;
6、協(xié)助區(qū)域進(jìn)行產(chǎn)品知識(shí)及銷售技巧培訓(xùn),提升團(tuán)隊(duì)業(yè)務(wù)能力;
7、年度區(qū)域BP的制定和跟進(jìn),保證全年費(fèi)用預(yù)算管理不超10%。
任職要求:
1、本科及以上學(xué)歷,藥學(xué)、醫(yī)學(xué)、市場(chǎng)營(yíng)銷等相關(guān)專業(yè);
2、市場(chǎng)高敏銳度,基于市場(chǎng)數(shù)據(jù)分析能發(fā)現(xiàn)有利洞見(jiàn),策劃精準(zhǔn)市場(chǎng)活動(dòng),助力銷售;
3、KOL管理能力,有新產(chǎn)品拓展能力;
4、學(xué)習(xí)能力強(qiáng),勇于擔(dān)當(dāng),敢于突破和卓越團(tuán)隊(duì)管理能力;
5、團(tuán)結(jié)協(xié)作,敏捷行動(dòng),卓越執(zhí)行力;
6、產(chǎn)品領(lǐng)域:呼吸領(lǐng)域、風(fēng)濕免疫和腫瘤領(lǐng)域
7、市場(chǎng)區(qū)域:魯皖晉蒙

工作地點(diǎn)

濟(jì)南歷下區(qū)山東大學(xué)齊魯醫(yī)院

職位發(fā)布者

鄧女士/人事經(jīng)理

立即溝通
公司Logo北京康蒂尼藥業(yè)股份有限公司
北京康蒂尼藥業(yè)股份有限公司創(chuàng)立于2002年,是一家以器官纖維化疾病為核心,集研發(fā)、生產(chǎn)、銷售于一體的創(chuàng)新藥物開(kāi)發(fā)企業(yè)。北京康蒂尼為美國(guó)納斯達(dá)克上市公司Gyre Therapeutics, Inc.(股票簡(jiǎn)稱:GYRE)的控股子公司。作為器官纖維化領(lǐng)域的先行者,公司的旗艦產(chǎn)品1.1類新藥艾思瑞?(吡非尼酮膠囊)是全球唯二已獲批且受指南推薦的特發(fā)性肺纖維化(IPF)治療藥物,也是國(guó)內(nèi)首款用于治療IPF的創(chuàng)新藥物,2014年成功上市后填補(bǔ)了該領(lǐng)域的空白。公司下一階段關(guān)鍵性產(chǎn)品—治療肝纖維化的F351(羥尼酮)被藥審中心認(rèn)定為“突破性治療藥物”,有望成為全球首款獲批治療慢性乙肝(CHB)相關(guān)纖維化的藥物。公司將通過(guò)艾思瑞?積累的從自主開(kāi)發(fā)到商業(yè)化成功的完整經(jīng)驗(yàn)豐富并推進(jìn)產(chǎn)品管線,將治療領(lǐng)域逐漸拓寬至其他器官纖維化,研究和開(kāi)發(fā)治療肺纖維化、肝纖維化及腎纖維化的創(chuàng)新藥品,為更多器官纖維化患者帶來(lái)新希望。Beijing Continent Co., Ltd was founded in 2002, which is a innovate drug development enterprise committed to organ fibrosis diseases, and integrated R&D, production and commercialization. Beijing Continent is the holding subsidiary of the NASDAQ-listed company Gyre Therapeutics, Inc.(Stock Ticker: GYRE).s a pioneer in the field of anti-organ fibrosis, company’s flagship product Class 1.1 new drug ETUARY?(Pirfenidone Capsule) is one of the only two types approved drugs for IPF treatment worldwide. As the first innovate drug approved to be used for IPF in China, it filled the gap in the IPF treatment field after its successful launch in 2014. F351(Hydronidone) the company’s key production for next stage, was granted a Breakthrough Therapy designation as the liver fibrosis treatment drug by the CDE. It is expected to be the first approved drug for the treatment of liver fibrosis associated with CHB.The company will enrich and boost the product pipeline by utilizing our successful and complete experience accumulated from in-house development to commercialization of ETUARY?. We are expanding our therapeutic field to other organs fibrosis by researching and developing the treatment of pulmonary fibrosis, liver fibrosis and renal fibrosis to bring new hope to the patients with organs fibrosis.
公司主頁(yè)